Role of solid lipid nanoparticles as drug delivery vehicles on the pharmacokinetic variability of Erlotinib HCl
Authors:
- Rajani RampakaRRRajani Rampaka
- Kusuma OmmiKOKusuma Ommi
- Naveen ChellaNaveen Chella
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 66
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochlorideInternational Journal of Pharmaceutics, 2012
- Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administrationColloids and Surfaces B: Biointerfaces, 2012
- Solid lipid nanoparticles: an oral bioavailability enhancer vehicleExpert Opinion on Drug Delivery, 2011
- A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasmaJournal of Chromatography B, 2011
- The size of solid lipid nanoparticles: An interpretation from experimental designColloids and Surfaces B: Biointerfaces, 2011
- Lipid Nanoparticles with a Solid Matrix (SLN®, NLC®, LDC®) for Oral Drug DeliveryDrug Development and Industrial Pharmacy, 2008
- Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystalsInternational Journal of Pharmaceutics, 2006
- The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in humanInternational Journal of Pharmaceutics, 2004
- Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanismEuropean Journal of Pharmaceutics and Biopharmaceutics, 1998
- Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN)International Journal of Pharmaceutics, 1997